Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback